Form 4: Apellis Pharmaceuticals CEO Cedric Francois Reports Changes in Beneficial Ownership Following Divorce Settlement

Apellis Pharmaceuticals CEO Cedric Francois reported a change in beneficial ownership of company stock due to a divorce settlement, involving a transfer of shares from one trust to his former spouse.

Summary

• Cedric Francois, CEO of Apellis Pharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The filing indicates a transfer of 182,146 shares of common stock from The Cedric Francois Irrevocable Trust of 2023 to Juliana Grossi as part of a divorce settlement on November 1, 2024.
• Francois also indirectly owns shares through several trusts, including The Cedric Francois Irrevocable Trust of 2023, The Cedric Francois Irrevocable Trust of 2023 2, The Francois Grossi Trust, and The Francois-DuBois Educational Trust.
• He disclaims beneficial ownership of shares held by these trusts except to the extent of his pecuniary interest.
• Following the reported transaction, Francois directly owns 313,662 shares and indirectly owns a total of 1,549,422 shares through the various trusts.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of a personal financial matter (divorce settlement) impacting stock ownership, with no inherent positive or negative implications for the company's performance.

Industry Context

Changes in beneficial ownership are common, especially among executives, and are closely monitored by investors for insights into management's confidence in the company and potential future actions.

Stakeholder Impact

• The change in ownership may be of interest to shareholders, but is unlikely to have a direct impact on the company's operations or financial performance.

Key Dates